로딩 중…
StockDiggingStockDigging

DuChemBIO Co.,Ltd.

176750· KOSDAQ
₩6,290-4.84%
2026-06-19

Price Chart

DuChemBIO Co.,Ltd.-41.71%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap179.19B KRW
Revenue39.82B KRW
Net Income3.81B KRW
Total Assets77.20B KRW
Net Assets50.11B KRW
Employees141
Value
P/E47.03x
P/B3.58x
PEG0.36x
P/S4.50x
EV/EBITDA47.12x
FCF Yield5.06%
Profitability
ROE7.60%
ROA4.94%
Op. Margin8.97%
Revenue Growth14.72%
Earnings Growth130.99%
Financial Health
Debt Ratio154.06%
Total Debt5.94B KRW
FCF9.07B KRW
Cash16.82B KRW
Current Ratio1.69x
Net Debt/EBITDA-3.05x
Performance
1Y Return-41.71%
1M Return-18.63%
From 52W High-50.74%
1Y MDD-50.77%
Trading
Volume31,382 shares
Foreign Own.0.96%
Per Share
EPS245 KRW
BPS1,768 KRW

Company Info

CEO 김상우
Employees 141
Founded 2002
HQ 서울특별시 마포구, KR

DuChemBio was established in 2002 for the development, manufacturing, and sales of radiopharmaceuticals for cancer and brain disease diagnosis and treatment, completing its KOSDAQ transfer listing in 2024. The company holds the largest number of PET-CT pharmaceuticals in Korea and operates 12 GMP-certified manufacturing facilities, achieving the top market share in major product categories. With a "First-in-Class" strategy for diagnostics and "Best-in-Class" for therapeutics, DuChemBio is striving to become a specialized radiopharmaceutical platform company in Asia. DuChemBio was established in 2002 and is headquartered in Mapo-gu, Seoul.